CoChat

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Open access
Augsberger, Christian, Hänel, Gerulf, Xu, Wei, Pulko, Vesna, Hanisch, Lydia Jasmin, Augustin, Angelique, Challier, John, Hunt, Katharina, Vick, Binje, Rovatti, Pier Eduardo, Krupka, Christina, Rothe, Maurine, Schönle, Anne, Sam, Johannes, Lezan, Emmanuelle, Ducret, Axel, Ortiz-Franyuti, Daniela, Walz, Antje-Christine, Benz, Jörg, Bujotzek, Alexander, Lichtenegger, Felix S., Gassner, Christian, Carpy, Alejandro, Lyamichev, Victor, Patel, Jigar, Konstandin, Nikola, Tunger, Antje, Schmitz, Marc, von Bergwelt-Baildon, Michael, Spiekermann, Karsten, Vago, Luca, Jeremias, Irmela, Marrer-Berger, Estelle, Umaña, Pablo, Klein, Christian, Subklewe, Marion · 2021 · Blood
Cited by 69

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Antibody-based immunotherapy is a promising strategy for targeting chemoresistant leukemic cells. However, classical antibody-based approaches are restricted to targeting lineage-specific cell surface antigens. By targeting intracellular antigens, a large number of other leukemia-associated targets would become accessible. In this study, we evaluated a novel T-cell bispecific (TCB) antibody, generated by using CrossMAb and knob-into-holes technology, containing a bivalent T-cell receptor–like binding domain that recognizes the RMFPNAPYL peptide derived from the intracellular tumor antigen Wilms tumor protein (WT1) in the context of HLA-A*02. Binding to CD3ε recruits T cells irrespective of their T-cell receptor specificity. WT1-TCB elicited antibody-mediated T-cell cytotoxicity against AML cell lines in a WT1- and HLA-restricted manner. Specific lysis of primary acute myeloid leukemia (AML) cells was mediated in ex vivo long-term cocultures by using allogeneic (mean ± standard error of the mean [SEM] specific lysis, 67 ± 6% after 13-14 days; n = 18) or autologous, patient-derived T cells (mean ± SEM specific lysis, 54 ± 12% after 11-14 days; n = 8). WT1-TCB–treated T cells exhibited higher cytotoxicity against primary AML cells than an HLA-A*02 RMF-specific T-cell clone. Combining WT1-TCB with the immunomodulatory drug lenalidomide further enhanced antibody-mediated T-cell cytotoxicity against primary AML cells (mean ± SEM specific lysis on days 3-4, 45.4 ± 9.0% vs 70.8 ± 8.3%; P = .015; n = 9-10). In vivo, WT1-TCB–treated humanized mice bearing SKM-1 tumors exhibited a significant and dose-dependent reduction in tumor growth. In summary, we show that WT1-TCB facilitates potent in vitro, ex vivo, and in vivo killing of AML cell lines and primary AML cells; these results led to the initiation of a phase 1 trial in patients with relapsed/refractory AML (#NCT04580121).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020010477

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 69

Metadata

Authors
Augsberger, C., Hänel, G., Xu, W., Pulko, V., Hanisch, L. J., Augustin, A., Challier, J., Hunt, K., Vick, B., Rovatti, P. E., Krupka, C., Rothe, M., Schönle, A., Sam, J., Lezan, E., Ducret, A., Ortiz-Franyuti, D., Walz, A.-C., Benz, J., Bujotzek, A., Lichtenegger, F. S., Gassner, C., Carpy, A., Lyamichev, V., Patel, J., Konstandin, N., Tunger, A., Schmitz, M., von Bergwelt-Baildon, M., Spiekermann, K., Vago, L., Jeremias, I., Marrer-Berger, E., Umaña, P., Klein, C., & Subklewe, M.
Venue
Blood
Published
2021-12-23
Volume
138
Issue
25
Pages
2655-2669
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3184041689
Cited by
69
References
5
FWCI
6.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. https://app.cochat.ai/papers/10.1182/blood.2020010477
The paper
Augsberger, C., Hänel, G., Xu, W., Pulko, V., Hanisch, L. J., Augustin, A., Challier, J., Hunt, K., Vick, B., Rovatti, P. E., Krupka, C., Rothe, M., Schönle, A., Sam, J., Lezan, E., Ducret, A., Ortiz-Franyuti, D., Walz, A.-C., Benz, J., . . . Subklewe, M. (2021). Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. https://doi.org/10.1182/blood.2020010477

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.